Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TPV low
Drug: Placebo
Drug: TPV high
Drug: Moxifloxacin
Drug: RTV

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 81

Registration Number: NCT02248883

Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Low dose of BIIL 284 BS tablets
Drug: Medium dose of BIIL 284 BS tablets
Drug: High dose of BIIL 284 BS tablets
Drug: Placebo

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 577

Registration Number: NCT02249247

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Pramipexole

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2644

Registration Number: NCT02248155

Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Methadone

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT02245451

FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)

Phase 2

Completed

Conditions: Prostate Hyperplasia

Interventions: Drug: FLOMAX® capsules
Drug: Placebo capsules

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 176

Registration Number: NCT02244294

Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: Tamsulosin

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 982

Registration Number: NCT02245529

Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: ALNA®

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4575

Registration Number: NCT02244333

Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia

Phase 4

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: Tamsulosin hydrochloride

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 493

Registration Number: NCT02244242

Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension

Completed

Conditions: Hypertension

Interventions: Drug: Telmisartan

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 13066

Registration Number: NCT02245464

Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: Tamsulosin

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 7391

Registration Number: NCT02245503

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy